Relmada Therapeutics Announces Efficacy And Safety Results From The Phase 3 Long-Term Study Of REL-1017 In Major Depressive Disorder
Portfolio Pulse from Benzinga Newsdesk
Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced positive efficacy and safety results from the Phase 3 long-term study of REL-1017 in patients with Major Depressive Disorder (MDD). The study showed that patients treated with REL-1017 experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment. The drug was well-tolerated with low rates of adverse events and discontinuations due to adverse events. No new safety signals were detected.
September 20, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Relmada Therapeutics' stock could see a positive impact following the announcement of positive results from the Phase 3 study of REL-1017 for Major Depressive Disorder. The positive results could potentially lead to regulatory approval and commercialization of the drug, which would be a significant revenue driver for the company.
Positive clinical trial results are a key catalyst for biotech stocks. The positive Phase 3 results for REL-1017 indicate that the drug is effective and safe, which increases the likelihood of regulatory approval. If approved, REL-1017 could be a significant revenue driver for Relmada Therapeutics, which would likely have a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100